Diligent Announces Diligent AI to Empower Governance, Risk and Compliance Professionals to Better Manage and Respond to Risk
11.6.2024 15:00:00 EEST | Business Wire | Press release
Diligent, a leading GRC SaaS company, today announced Diligent AI, a powerful set of artificial intelligence capabilities within the Diligent One Platform that enhance how organizations understand, anticipate and mitigate risks. Diligent AI will enable users to identify risks, safeguard data and democratize the decision-making processes, driving resilience and empowering organizations with certainty and clarity like never before.
"Company leaders face a dynamic and evolving risk environment. It’s imperative to turn data into strategic intelligence to anticipate and prevent risks, rather than just respond to them,” said Brian Stafford, President and CEO of Diligent. “Diligent’s AI-enhanced platform is uniquely positioned to connect all aspects of governance, risk and compliance, delivering customized insights to elevate governance and clarify risk.”
Diligent AI helps leaders amplify critical insights while working together across the organization, using risk as a shared language. Leaders can expand resources and achieve greater results through integrated automation, enhance stakeholder communication by tailoring information to board members, chief financial officers, chief risk officers and other executives, and enhance decision making by breaking down information silos across governance, risk and compliance (GRC) functions.
Register for the first session in Diligent’s AI webinar series starting on June 13, where Diligent leaders and experts will discuss Diligent AI capabilities and how they:
Elevate Governance for Boards and Leaders:
- Creating efficient, context-aware summaries of board materials to help directors easily digest information and glean insights.
- Providing AI-powered insights into a company’s ESG focus and self-disclosed risk factors, enabling peer comparison and helping to identify industry trends.
- Quickly assisting with boards-related questions through a 24/7 AI-powered virtual assistant.
Clarify Risk for Audit, Risk and Compliance Teams:
- Simplifying the tedious process of mapping internal controls to regulatory requirements, enabling GRC professionals to efficiently demonstrate compliance.
- Identifying changes between two versions of the same regulation, categorizing them as significant, moderate or minor, enabling users to efficiently update related policies, risks and controls.
- Empowering users to create, edit and troubleshoot data integrations and data analytics scripts using plain language. This brings Diligent's powerful robotics capabilities (also known as ACL Analytics) to a broader audience.
Additional capabilities will be added to Diligent AI over the coming months that empower GRC professionals to better mitigate risks and stay on top of changing regulatory requirements, and help corporate directors govern more effectively amidst escalating risks and information overload.
“Diligent AI adds to the breadth of the Diligent One Platform by enabling leaders to more quickly and effectively respond to risk in a competitive environment,” said Phil Lim, Global AI Champion at Diligent. “Our thoughtful and ethical approach to AI use, guided by industry-leading principles, means customers can feel secure in knowing that AI interacts with their data safely and securely, and only with their prior consent.”
The use of Generative AI in GRC must uphold the highest standards of safety and security, and Diligent has committed to the safe, secure and ethical use of AI through its guiding principles. This ensures users’ data stays their own, generated content is clearly labelled and users must always opt-in before using AI with their data. Learn more about Diligent’s AI Principles here.
About Diligent
Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.
Follow Diligent on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611912292/en/
Contacts
Media
Julia Stoyanov
Communications Director, Diligent
+1 (604) 669-4225
Jhanbury@diligent.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom